secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001558370-23-011868
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics shareholders approve increase in authorized common shares from 144M to 185M
--------------------------------------------------------------------------------

- Amendment to Certificate of Incorporation approved at reconvened 2023 Annual Meeting on July 13, 2023.
- Authorized common shares increased by 41M, from 144M to 185M.
- Votes: 33,870,055 for, 9,479,063 against, 1,042,433 abstentions.
- Proposal passed with approximately 76% of votes cast in favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023011868/0001558370-23-011868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023011868/plx-20230713x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-011868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer